Targeting Lysine-Specific Demethylase 1 Rescues Major Histocompatibility Complex Class I Antigen Presentation and Overcomes Programmed Death-Ligand 1 Blockade Resistance in SCLC

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

(2021) D.R. Spigel et al.   ANNALS OF ONCOLOGY

Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity

(2021) Navin R. Mahadevan et al.   Cancer Discovery

Simultaneous Inhibition of LSD1 and TGF-B Enables Eradication of Poorly Immunogenic Tumors with anti-PD-1 Treatment

(2021) Wanqiang Sheng et al.   Cancer Discovery

Cell-autonomous immune gene expression is repressed in pulmonary neuroendocrine cells and small cell lung cancer

(2021) Ling Cai et al.   Communications Biology

Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung cancer

(2021) Nitin Roper et al.   Nature Communications

Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer

(2021) Joseph M. Chan et al.   CANCER CELL

Confronting false discoveries in single-cell differential expression

(2021) Jordan W. Squair et al.   Nature Communications

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade

(2021) Yi Liu et al.   Nature Communications

Quantitative Proteomics of the Cancer Cell Line Encyclopedia

(2020) David P. Nusinow et al.   CELL

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

(2020) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

Harnessing natural killer immunity in metastatic small cell lung cancer

(2020) Sarah A. Best et al.   Journal of Thoracic Oncology

Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution

(2020) David Dora et al.   Molecular Oncology

Targeting Nuclear LSD1 to Reprogram Cancer Cells and Reinvigorate Exhausted T Cells via a Novel LSD1-EOMES Switch

(2020) Wen Juan Tu et al.   Frontiers in Immunology

SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures

(2020) Camille Tlemsani et al.   Cell Reports

Concurrent Mutations in STK11 and KEAP1 Promote Ferroptosis Protection and SCD1 Dependence in Lung Cancer

(2020) Corrin A. Wohlhieter et al.   Cell Reports

Targeting NOTCH activation in small cell lung cancer through LSD1 inhibition

(2019) Arnaud Augert et al.   Science Signaling

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer

(2019) Abel H. Y. Tan et al.   Frontiers in Immunology

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

(2019) Marian L. Burr et al.   CANCER CELL

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

(2019) Hyun Cheol Chung et al.   Journal of Thoracic Oncology

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia

(2018) Tamara Maes et al.   CANCER CELL

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

(2018) Wanqiang Sheng et al.   CELL

Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses

(2018) Israel Cañadas et al.   NATURE MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

(2018) Ye Qin et al.   ONCOGENE

Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study

(2017) Patrick A. Ott et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential analysis of RNA-seq incorporating quantification uncertainty

(2017) Harold Pimentel et al.   NATURE METHODS

Salmon provides fast and bias-aware quantification of transcript expression

(2017) Rob Patro et al.   NATURE METHODS

Ensembl 2018

(2017) Daniel R Zerbino et al.   NUCLEIC ACIDS RESEARCH

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting

(2017) Kazuyoshi Takeda et al.   Nature Communications

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

Complex heatmaps reveal patterns and correlations in multidimensional genomic data

(2016) Zuguang Gu et al.   BIOINFORMATICS

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer

(2016) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC

(2016) Edurne Arriola et al.   Journal of Thoracic Oncology

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

Comprehensive genomic profiles of small cell lung cancer

(2015) Julie George et al.   NATURE

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes

(2014) Anna M. Varghese et al.   Journal of Thoracic Oncology

A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines

(2014) Sebastian Boegel et al.   OncoImmunology

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

An Optimized microRNA Backbone for Effective Single-Copy RNAi

(2013) Christof Fellmann et al.   Cell Reports

NLRC5, at the Heart of Antigen Presentation

(2013) Andreas Neerincx et al.   Frontiers in Immunology

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†

(2012) M. Reck et al.   ANNALS OF ONCOLOGY

Systematic identification of genomic markers of drug sensitivity in cancer cells

(2012) Mathew J. Garnett et al.   NATURE

Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer

(2012) Charles M Rudin et al.   NATURE GENETICS

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

(2012) Martin Peifer et al.   NATURE GENETICS

clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters

(2012) Guangchuang Yu et al.   OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Cigarette smoking and lung cancer-relative risk estimates for the major histological types from a pooled analysis of case-control studies

(2011) Beate Pesch et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma

(2010) B. E. Schaffer et al.   CANCER RESEARCH

The Nucleotide-Binding Oligomerization Domain-Like Receptor NLRC5 Is Involved in IFN-Dependent Antiviral Immune Responses

(2010) Sven Kuenzel et al.   JOURNAL OF IMMUNOLOGY

Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research

(2010) Adi F. Gazdar et al.   JNCI-Journal of the National Cancer Institute

Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi

(2010) Johannes Zuber et al.   NATURE BIOTECHNOLOGY

NLR family member NLRC5 is a transcriptional regulator of MHC class I genes

(2010) T. B. Meissner et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes

(2008) Tanja Ninkovic et al.   MOLECULAR IMMUNOLOGY